ATE244016T1 - Protein der ausseren membran von moraxella catarrhalis omp-106, dessen gensequenz und dessen verwendung - Google Patents

Protein der ausseren membran von moraxella catarrhalis omp-106, dessen gensequenz und dessen verwendung

Info

Publication number
ATE244016T1
ATE244016T1 AT97926409T AT97926409T ATE244016T1 AT E244016 T1 ATE244016 T1 AT E244016T1 AT 97926409 T AT97926409 T AT 97926409T AT 97926409 T AT97926409 T AT 97926409T AT E244016 T1 ATE244016 T1 AT E244016T1
Authority
AT
Austria
Prior art keywords
gene sequence
membrane protein
outer membrane
moraxella catarrhalis
omp
Prior art date
Application number
AT97926409T
Other languages
German (de)
English (en)
Inventor
Kenneth Tucker
Laura Plosila
Original Assignee
Antex Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biolog Inc filed Critical Antex Biolog Inc
Application granted granted Critical
Publication of ATE244016T1 publication Critical patent/ATE244016T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97926409T 1996-05-03 1997-04-28 Protein der ausseren membran von moraxella catarrhalis omp-106, dessen gensequenz und dessen verwendung ATE244016T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/642,712 US7341727B1 (en) 1996-05-03 1996-05-03 M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
PCT/US1997/007679 WO1997041731A1 (en) 1996-05-03 1997-04-28 Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof

Publications (1)

Publication Number Publication Date
ATE244016T1 true ATE244016T1 (de) 2003-07-15

Family

ID=24577687

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97926409T ATE244016T1 (de) 1996-05-03 1997-04-28 Protein der ausseren membran von moraxella catarrhalis omp-106, dessen gensequenz und dessen verwendung

Country Status (25)

Country Link
US (6) US7341727B1 (enExample)
EP (1) EP0900025B1 (enExample)
JP (2) JP4401437B2 (enExample)
CN (2) CN1222618C (enExample)
AR (1) AR006999A1 (enExample)
AT (1) ATE244016T1 (enExample)
AU (1) AU723528B2 (enExample)
BG (1) BG64832B1 (enExample)
BR (1) BR9711090A (enExample)
CA (1) CA2253636C (enExample)
CZ (1) CZ298034B6 (enExample)
DE (1) DE69723254T2 (enExample)
EA (1) EA002743B1 (enExample)
EE (1) EE04684B1 (enExample)
ES (1) ES2202624T3 (enExample)
GE (1) GEP20022695B (enExample)
HU (1) HU223004B1 (enExample)
NO (2) NO324816B1 (enExample)
NZ (1) NZ332896A (enExample)
PL (3) PL189375B1 (enExample)
SK (1) SK284812B6 (enExample)
TW (1) TW541314B (enExample)
UA (1) UA68332C2 (enExample)
WO (1) WO1997041731A1 (enExample)
ZA (1) ZA973809B (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
GB9808720D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
EP1078065A2 (en) * 1998-05-12 2001-02-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Compounds from moraxella catarrhalis
GB9810193D0 (en) * 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
US6673910B1 (en) 1999-04-08 2004-01-06 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics
WO2000071724A2 (en) * 1999-05-24 2000-11-30 Smithkline Beecham Biologicals S.A. Novel compounds from moraxella catarrhalis
GB9915031D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
GB9921691D0 (en) * 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
DE60035788T2 (de) * 1999-09-14 2008-04-30 Glaxosmithkline Biologicals S.A. Polypeptide aus moraxella (branhamella) catarrhalis
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
SE0102410D0 (sv) * 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
WO2004014417A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
KR102017842B1 (ko) 2005-04-08 2019-09-03 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
CN100357318C (zh) * 2005-10-11 2007-12-26 中山大学 美人鱼发光杆菌外膜蛋白w和编码序列及其制备方法和应用
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EA014107B1 (ru) 2005-12-22 2010-10-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
EA015561B1 (ru) 2006-01-17 2011-08-30 Арне Форсгрен НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE)
EP2038297A4 (en) 2006-06-27 2010-03-03 Oral Health Australia Pty Ltd PORPHYROMONAS GINGIVALIS POLYPEPTIDES SUITABLE FOR PREVENTION OF PERIODONTITIS
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
WO2009006699A1 (en) * 2007-07-12 2009-01-15 Oral Health Australia Pty Ltd Biofilm treatment
EP2604692A1 (en) 2007-07-12 2013-06-19 Oral Health Australia Pty Ltd Immunology treatment for biofilms
US8642046B2 (en) * 2007-10-09 2014-02-04 Tufts University Cholera vaccines
AU2009287340B2 (en) 2008-08-29 2015-03-19 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of P.gingivalis infection
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
ES2366735B1 (es) * 2009-10-08 2012-09-13 Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla Vacuna frente a acinetobacter baumannii.
US9500645B2 (en) 2009-11-23 2016-11-22 Cyvek, Inc. Micro-tube particles for microfluidic assays and methods of manufacture
US9759718B2 (en) 2009-11-23 2017-09-12 Cyvek, Inc. PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use
US9855735B2 (en) 2009-11-23 2018-01-02 Cyvek, Inc. Portable microfluidic assay devices and methods of manufacture and use
US9651568B2 (en) 2009-11-23 2017-05-16 Cyvek, Inc. Methods and systems for epi-fluorescent monitoring and scanning for microfluidic assays
US10065403B2 (en) 2009-11-23 2018-09-04 Cyvek, Inc. Microfluidic assay assemblies and methods of manufacture
US9700889B2 (en) 2009-11-23 2017-07-11 Cyvek, Inc. Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results
ES2649559T3 (es) 2009-11-23 2018-01-12 Cyvek, Inc. Método y aparato para realizar ensayos
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
BR112012022669A2 (pt) 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
ES2608475T3 (es) 2010-04-13 2017-04-11 Celldex Therapeutics, Inc. Anticuerpos que se unen a cd27 humana y usos de los mismos
WO2011137334A1 (en) * 2010-04-30 2011-11-03 The Research Foundation Of State University Of New York Compositions and methods for stimulating immune response against moraxella catarrhalis
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
CN106552682B (zh) 2011-03-22 2020-06-19 西维克公司 微流体装置以及制造方法和用途
RU2481401C2 (ru) * 2011-07-15 2013-05-10 Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГОУ ВПО УГМА Минздравсоцразвития России) СПОСОБ ВЫЯВЛЕНИЯ β-ЛАКТАМАЗОПРОДУЦИРУЮЩИХ ОКСИДАЗОПОЗИТИВНЫХ ГРАМОТРИЦАТЕЛЬНЫХ ДИПЛОКОККОВ, ПОДОЗРИТЕЛЬНЫХ НА ПРИНАДЛЕЖНОСТЬ К MORAХELLA (BRANCHAMELLA) CATARRHALIS
KR102114734B1 (ko) 2012-03-08 2020-05-25 싸이벡, 아이엔씨 미세유체 분석 장치용 마이크로튜브 입자 및 제조방법
US11210432B2 (en) * 2013-08-20 2021-12-28 Janus Technologies, Inc. Method and apparatus for selectively snooping and capturing data for secure computer interfaces
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10228367B2 (en) 2015-12-01 2019-03-12 ProteinSimple Segmented multi-use automated assay cartridge
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2577232B (en) 2017-05-30 2022-07-06 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
JP7466459B2 (ja) 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド 抗ｃｄ２７および抗ｐｄ－ｌ１抗体ならびに二重特異性構築物
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
CN111157735B (zh) * 2018-11-07 2023-02-07 广州万孚生物技术股份有限公司 凝集性卡他莫拉菌单克隆抗体及其制备方法和应用
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
CA3142300C (en) 2019-06-05 2025-02-04 Glaxosmithkline Biologicals Sa SAPONIN PURIFICATION
CN111778226B (zh) * 2020-07-21 2022-04-05 东北师范大学 一种水稻耐碱胁迫相关的质膜H+-ATPase蛋白及其应用
BR112023020303A2 (pt) 2021-04-09 2023-11-14 Celldex Therapeutics Inc Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675176A (en) * 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
GB9809683D0 (en) 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9812163D0 (en) 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
AU723528B2 (en) 2000-08-31
US20080145916A1 (en) 2008-06-19
HUP9902695A3 (en) 2001-02-28
EP0900025B1 (en) 2003-07-02
GEP20022695B (en) 2002-05-27
JP4401437B2 (ja) 2010-01-20
EP0900025A4 (en) 2000-01-05
US7128910B2 (en) 2006-10-31
PL330935A1 (en) 1999-06-07
EE04684B1 (et) 2006-08-15
NO324816B1 (no) 2007-12-10
PL189375B1 (pl) 2005-07-29
CZ298034B6 (cs) 2007-05-30
UA68332C2 (en) 2004-08-16
CN1222618C (zh) 2005-10-12
EE9800373A (et) 1999-04-15
CA2253636C (en) 2003-04-22
US6214981B1 (en) 2001-04-10
NO985113L (no) 1998-12-28
TW541314B (en) 2003-07-11
NO985113D0 (no) 1998-11-02
BG102983A (en) 2000-05-31
US20100021492A1 (en) 2010-01-28
CA2253636A1 (en) 1997-11-13
CN100415871C (zh) 2008-09-03
JP2000510696A (ja) 2000-08-22
US20070087019A1 (en) 2007-04-19
US7341727B1 (en) 2008-03-11
DE69723254D1 (de) 2003-08-07
HK1021299A1 (en) 2000-06-09
ES2202624T3 (es) 2004-04-01
HK1095358A1 (zh) 2007-05-04
HU223004B1 (hu) 2004-03-01
ZA973809B (en) 1997-12-01
US7576179B2 (en) 2009-08-18
AR006999A1 (es) 1999-10-13
CN1223549A (zh) 1999-07-21
JP2008161194A (ja) 2008-07-17
NO20063711L (no) 1998-12-28
BG64832B1 (bg) 2006-06-30
US7914795B2 (en) 2011-03-29
BR9711090A (pt) 1999-08-17
SK284812B6 (sk) 2005-12-01
AU3118097A (en) 1997-11-26
HUP9902695A2 (hu) 1999-12-28
CN1800359A (zh) 2006-07-12
DE69723254T2 (de) 2004-04-22
PL189374B1 (pl) 2005-07-29
PL189995B1 (pl) 2005-10-31
EP0900025A1 (en) 1999-03-10
NZ332896A (en) 2000-05-26
EA002743B1 (ru) 2002-08-29
SK150998A3 (en) 1999-05-07
CZ352498A3 (cs) 1999-06-16
EA199800973A1 (ru) 1999-06-24
US20020177200A1 (en) 2002-11-28
WO1997041731A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
ATE244016T1 (de) Protein der ausseren membran von moraxella catarrhalis omp-106, dessen gensequenz und dessen verwendung
DE68910713D1 (de) Isolierung, Reinigung, Charakterisierung, Klonierung und Sequenzierung von N-alpha-Acetyltransferase.
DE69732871D1 (de) Basisches Protein Zusammensetzung, basisches Peptid Zusammensetzung und deren Verwendung
EP0571442A4 (en) PROTEIN TSG-14 INDUCED BY CYTOKINE, DNA ENCODING THE PROTEIN AND USES THEREOF.
EE04817B1 (et) Kudede regeneratsiooni modulaatorid
AU5394196A (en) High molecular weight major outer membrane protein of moraxella
FI962247A7 (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden kä yttömenetelmät
DE69737044D1 (de) Herstellung von fugizides Chinazolinonen und nützliche Zwischenprodukte
EP0733122A4 (en) FUSION PROTEINS CONTAINING REP VIRUS PROTEIN ASSOCIATED WITH ADENOVIRUS AND BACTERIAL PROTEIN
ATE277184T1 (de) Trichoderma reesei swollenin protein und dafür kodierende dns sequenz
EP0875567A3 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
AU4075797A (en) Outer membrane protein b1 of moraxella catarrhalis
FI953640L (fi) Termostabiilit ksylanaasi-DNA, proteiini ja käyttömenetelmät
EP1012297A4 (en) GENES CODING POLYPHENOLOXIDASE, EXTRACTS FROM BANANAS, TOBACCO AND PINEAPPLES
DE69728897D1 (de) Saeugetierchemokine
DE69329164D1 (de) Protein mit Alpha-Glukosidase-Aktivität, DNS mit dessen genetischer Information und Herstellung von Alpha-Glukosidase
ATE286908T1 (de) Gewebespezifische expression des retinoblastoma- proteins
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung
EE9900092A (et) PTX-tundlikud G-valgud, nende valmistamine ja kasutamine
DE69709021D1 (de) Reinigung von Pentafluorethan
HK1016424A (en) Protein-106 polypeptide of the outer membrane of moraxella catarrhalis, gene sequence and uses thereof
DE69718579D1 (de) Bestimmung von Proteinen
ATE166067T1 (de) Kalzium-kanal-blockierende polypeptide aus theraphosidae aphonopelma
DE69706786D1 (de) Herstellung von Norlabdan-Oxid-Zwischenprodukten
ATE97442T1 (de) Isolierung, reinigung, charakterisierung, klonierung und sequenzierung von n-alphaacetyltransferase.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties